2017 Industry Supported Sessions

 

 

A great opportunity for registered delegates to attend sessions on specific topics of interest developed by CNSF and Industry.  These may be Lunch ‘n Learn sessions or late afternoon sessions with refreshments available.  See details below.

Pre-registration is required through the Congress registration process.

 

Tuesday, June 20, 2017    12:15 pm – 1:45 pm     Lunch ‘n Learn (unaccredited)

This program was developed by the CNSF and Novartis to achieve scientific integrity, objectivity and balance.  It is an unaccredited learning activity and not eligible for MOC credits.

 

Alzheimer’s and MS

CourseChairs:  Sandra Black and David Li 

Course Description:  New imaging techniques in MS:

A review of imaging techniques that are most immediately applicable in clinical MS practice.

Course Description:  Understanding Alzheimer’s Disease:

Review the differential diagnosis of Dementia and discuss best applicable therapeutic strategies

 

Tuesday, June 20, 2017    12:15 pm – 1:45 pm     Lunch ‘n Learn (unaccredited)

This program was developed by the CNSF and Biogen to achieve scientific integrity, objectivity and balance.  It is an unaccredited learning activity and not eligible for MOC credits.

Spinal muscular atrophy management update. Treatment with anti-sense makes sense.

Chair: Craig Campbell

Course Description:  Spinal muscular atrophy (SMA) is a rare, autosomal-recessive, neuromuscular disease caused by deletion or mutation of the survival motor neuron 1 (SMN1) gene. This gene is responsible for producing survival motor neuron (SMN) protein, which maintains the health and normal function of motor neurons.  Nusinersen is an antisense oligonucleotide that alters the SMN2 gene splicing to promote the production of full-length SMN protein and is currently under investigation for the treatment of SMA in Canada. This presentation will review the pathophysiology of SMA, as well as new insights on the treatment and management of SMA.

 

Tuesday, June 20, 2017    4:15 pm – 5:45 pm      Co-Sponsored session (unaccredited)

This program was developed by the CNSF and Sanofi Genzyme to achieve scientific integrity, objectivity and balance.  It is an unaccredited learning activity and not eligible for MOC credits.

Pompe Medical Panel Discussion

CourseChair:  Kristine Chapman

Course Description:  Pompe disease presents a diagnostic challenge for physicians due to the rarity, genetic and phenotypic heterogeneity and clinical overlap with other neuromuscular disorders, such as limb-girdle muscular dystrophy (LGMD), hereditary muscular dystrophies as well as hereditary and metabolic myopathies. Therefore, the diagnosis of Pompe disease is often delayed by years from onset of symptoms. Newer genetic testing, particularly those based on next generation sequencing, are valuable emerging tools to aid with the diagnostic challenge. This session will focus specifically on the opportunities and challenges of early and accurate diagnosis of patients with Pompe disease, with an emphasis on both clinical assessment and diagnostic tools.

 

Wednesday, June 21, 2017    12:45 pm – 2:15 pm     Co-Developed session

This program was developed by the CNSF and Antibody Communications, supported by Hoffmann-La Roche and was planned to achieve scientific integrity, objectivity and balance. 

Changing the course of MS: high efficacy therapeutic options

Course ChairsSarah Morrow & Fabrizio Giuliani

Course Description:   This program will explore the newest developments and approaches to its optimal management and the impact of early disease activity on long-term outcomes. It will critically evaluate the risk-benefit profile of current and emerging high efficacy therapies, and their impact on disease activity and progression. It will discuss the short therapeutic window to influence disease progression and worsening, and the importance of early, effective treatment in this regard. Through evidence-based and practical discussions with the panel, the program hopes to elucidate the future of MS therapy and the role newer agents may play in helping patients achieve optimal outcomes.

 

Wednesday, June 21, 2017    12:45 pm – 2:15 pm     Co-Developed session

This program was developed by the CNSF and Eli Lilly and was planned to achieve scientific integrity, objectivity and balance. 

Recent Advances in CSF analysis in Cognitive Impairment

Course Chairs:   Sandra Black (chair) & Pedro Rosa-Neto

Course Description: This co-developed session aims to discuss CSF biomarkers in development, their role in the diagnostic framework of AD and other dementias, and some methodological limitations; more details to follow shortly.

Thursday, June 22, 2017    11:45 am – 1:15 pm       Lunch ‘n Learn (unaccredited)

This program was developed by the CNSF and Sanofi Genzyme to achieve scientific integrity, objectivity and balance.  It is an unaccredited learning activity and not eligible for MOC credits.

The Long Term Implications of Selecting an Oral Disease Modifying Therapy

Course Chairs: Carolina Rush

Course Description:

  • Considering the long term data, what are the implications/considerations when selecting a first line oral agent?
  • How do oral DMT selections in the short term affect ‘switch’ choices in the long term?
  • How to decide between lateral switching vs. escalation considering the available long term data.

 

Thursday, June 22, 2017    4:00 pm – 5:30 pm   Co-Sponsored session (unaccredited)

This program was developed by the CNSF and EMD Serono to achieve scientific integrity, objectivity and balance.  It is an unaccredited learning activity and not eligible for MOC credits.

MS Duels Program

Course ChairMark Freedman

Course Description:  MS Duels is a debate style learning initiative that examines hot topics from 2 perspectives – allowing both the debaters and the participants to challenge their thinking around different areas pertaining to the management of MS.